Clinical Trial Update: A Pilot Study of Xifaxan to Treat Patients With PSC [Phase 1]

View source ↗

Summary

A Phase 1 pilot study investigated rifaximin (Xifaxan) as a treatment for primary sclerosing cholangitis, and the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sclerosing Cholangitis

Drugs mentioned

• XIFAXAN (rifaximin)

Snippet

Sponsor: Mayo Clinic | Conditions: Primary Sclerosing Cholangitis (PSC) | Phase 1 | Status: COMPLETED